/ /

CLINICAL

Aerie’s focus on therapies that address cause of vision lossAerie Pharmaceuticals is developing the first novel mechanism of action for the treatment of glaucoma in over 20 years. The company is developing two products for the treatment of patients with glaucoma and ocular hypertension. One is an entirely new agent, netarsudil, the other is a combination of netarsudil plus latanoprost.
B + L places focus on innovation in pharma, surgical, vision careBausch + Lomb (B + L) is more than one of the oldest eye care companies in the industry. It is also one of the broadest, with portfolios in contact lenses, consumer eye products, cataract surgery, intraocular lenses, retina surgery, and a wide range of ophthalmic pharmaceutical products.
Novartis Alcon changes build better platform for ophthalmologyAlcon Laboratories pharmaceutical products have been moved into the Novartis Pharmaceutical Division. The switch means a sharper focus on research and development in ophthalmology as well as better access to Norvartis’ patient services and support capabilities.
New technologies on horizon to redefine drug deliveryGlaucoma has an adherence problem. Drugs that are highly efficacious are far less than optimally effective because patients fail to take eye drops properly or don’t take them all. Novel drug-delivery technologies could improve adherence and outcomes.
Translatable animal model needed if glaucoma research is achievableAnimal models are vital to glaucoma research. The problem is that no single animal model fully recapitulates the natural history of human glaucoma. A model that mimicked the progression and time line of human glaucoma would do little to speed drug discovery.
Growing number of devices set to transform glaucoma treatmentMinimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. With two MIGS devices already approved in the United States, there are a variety of novel devices that have the potential to transform the treatment of glaucoma.
Shire utilizing biotech approach to meet unmet ophthalmic needsShire, which built its experience in biotech agents, is taking a biotech approach to meeting unmet needs in both the anterior and poster segments of ophthalmology.
Artificial intelligence will bring ‘reality’ to glaucoma diagnosisRobert Chang, MD, outlines how artificial intelligence might work in glaucoma.
5 reasons to upgrade patients from monovision to multifocalsMany optometrists use the “if it aint broke, don’t fix it” excuse for not fitting multifocals. It is time for ODs to get comfortable with multifocal contact lenses and the opportunity they provide our practices as well as the ability they give us to meet modern patient demands.
5 observations about corticosteroids for DME treatmentFindings from studies investigating intravitreal corticosteroids for treatment of diabetic macular edema (DME) provide information about their efficacy and safety, including some understanding of how they compare with anti-VEGF therapy.